Back to today’s briefing

Story perspectives

Supreme Court Upholds Generic ‘Skinny Labels’, Cuts Drug Costs

6/18/2026

46 4 Full Breakdown

Summary

Story summary

The Supreme Court issued a rare unanimous opinion, written by Justice Ketanji Brown Jackson.
It reversed the lower-court ruling in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma and held that a generic’s “skinny label” does not encourage patent infringement.
The decision may lower litigation risk for generics and speed cheaper drug entry, helping reduce U.S. prescription-drug spending.

1 of 1

Story summary

The Supreme Court issued a rare unanimous opinion, written by Justice Ketanji Brown Jackson.
It reversed the lower-court ruling in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma and held that a generic’s “skinny label” does not encourage patent infringement.
The decision may lower litigation risk for generics and speed cheaper drug entry, helping reduce U.S. prescription-drug spending.